Euroimmun Us, Inc.: FDA filings under this applicant name
FDA lists 30 510(k) clearances under 2 spellings of the applicant name “Euroimmun Us, Inc.” (first 2009, latest 2020), plus 1 De Novo decision, across 19 product codes in 3 review panels. Median 510(k) review time under this name: 268 days. Since 2017 the median was 268 days, against 176 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 2 | 406 |
| 2013 | 5 | 237 |
| 2014 | 3 | 314 |
| 2015 | 2 | 282 |
| 2016 | 3 | 268 |
| 2017 | 1 | 90 |
| 2018 | 3 | 268 |
| 2019 | 1 | 91 |
| 2020 | 1 | 310 |
| 2021 | 0 | — |
| 2022 | 0 | — |
| 2023 | 0 | — |
| 2024 | 0 | — |
| 2025 | 0 | — |
| 2026 | 0 | — |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Euroimmun Us, Inc. took a median 268 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 176 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| LSR | Reagent, Borrelia Serological Reagent | 3 | 3 |
| MOB | Test System, Antineutrophil Cytoplasmic Antibodies (Anca) | 3 | 3 |
| DHN | Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control | 2 | 2 |
| KTL | Anti-Dna Indirect Immunofluorescent Solid Phase | 2 | 2 |
| LKO | Anti-Rnp Antibody, Antigen And Control | 2 | 2 |
| MST | Antibodies, Gliadin | 2 | 2 |
| NIY | Autoantibodies, Anti-Soluble Liver Antigen (Sla), Autoimmune Hepatitis | 2 | 2 |
| NOP | Elisa, Antibody, West Nile Virus | 2 | 2 |
| OEG | Autoantibodies, Skin (Bullous Pemphigoid 180 And Bullous Pemphigoid 230 | 2 | 2 |
| PGV | Anti-Phospholipase A2 Receptor | 2 | 1 |
Plus 9 more product codes.
Review panels
- Immunology (25)
- Microbiology (5)
- Clinical Chemistry (1)
Most recent Euroimmun Us, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K193115 | EUROIMMUN Anti-BP230-CF ELISA (IgG) | OEG | 2020-09-17 | 310 |
| K183313 | EUROIMMUN Anti-tissue Transglutaminase ELISA (IgA), EUROIMMUN Anti-tissue Transglutaminase ELISA (IgG) | MVM | 2019-02-28 | 91 |
| K172582 | EUROIMMUN IFA Granulocyte Mosaic EUROPattern and EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern | MOB | 2018-05-24 | 269 |
| K172252 | EUROIMMUN IFA: Crithidia luciliae sensitive (anti-dsDNA) EUROPattern | KTL | 2018-04-20 | 268 |
| K172244 | EUROIMMUN IFA: Crithidia luciliae (anti-dsDNA) EUROPattern | KTL | 2018-04-20 | 268 |
| K172722 | Anti-Borrelia burgdorferi US EUROLINE-WB (IgM) | LSR | 2017-12-10 | 90 |
| K161513 | Anti-Borrelia burgdorferi US Westernblot (IgG) | LSR | 2016-08-25 | 84 |
| K153308 | EUROIMMUN Anti-West Nile Virus ELISA (IgM) | NOP | 2016-08-12 | 269 |
| K153303 | EUROIMMUN Anti-West Nile Virus ELISA (IgG) | NOP | 2016-08-10 | 268 |
| K142038 | EUROIMMUN LYME ELISA(IgG/IgM) | LSR | 2015-05-04 | 280 |
20 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN140002 | De Novo | Anti-Phospholipase A2 Receptor | 2014-05-29 |
Recalls
FDA recall records list no recalls under a recalling firm named Euroimmun Us, Inc..
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Euroimmun Us, Inc. (19)
- Euroimmun US (12)
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Euroimmun Us, LLC (6 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Euroimmun Us, Inc.?
FDA lists 30 510(k) clearances under 2 spellings of the applicant name “Euroimmun Us, Inc.” (first 2009, latest 2020), plus 1 De Novo decision, across 19 product codes in 3 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Euroimmun Us, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Euroimmun Us, Inc. is 268 days. Since 2017: 268 days, versus 176 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Euroimmun Us, Inc.?
The most frequent FDA product codes under this applicant name are LSR (Reagent, Borrelia Serological Reagent, 3); MOB (Test System, Antineutrophil Cytoplasmic Antibodies (Anca), 3); DHN (Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control, 2).
Next steps
- See all 30 Euroimmun Us, Inc. clearances with predicates and recalls
- Run predicate analysis for product code LSR, Euroimmun Us, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.